Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wanbury launches nitrofurantoin sustained-release in India

This article was originally published in Scrip

Executive Summary

Wanbury of India has launched nitrofurantoin 100mg sustained-release (marketed as Nitrofur SR) for the treatment of urinary tract infections (UTI) on the domestic market. The product, which is based on hydrophilic polymer matrix technology, offers a once-daily dosage. Currently, competing products fall in the instant-release category and need to be taken four times a day, often with side-effects such as gastrointestinal irritation and burning sensation, leading to poor patient compliance. The market for UTIs in India is estimated at about Rs12 billion ($247.3 million) and is growing at 14% per year. Wanbury is targeting sales of Rs100 million from Nitrofur SR in the first year. Wanbury, which was originally formed by the merger of Wander and Pearl Organics in India, is a manufacturer of metformin hydrochloride. Wander was originally a subsidiary of Sandoz, but the Indian founders took control of the company in 1995.

You may also be interested in...

Takeda Introduces Vedolizumab In India Amid Signs Of Gear Shift

Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.

APAC Cancer Preparedness Varied, Late Diagnosis A Key Challenge

A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.

Asia Deal Watch: Cipla’s Latest Diabetes Partner In India Is Boehringer Ingelheim

Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts